Search

Nabumetone

Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568] … [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.

Recombinant stabilized RSV B prefusion F antigen

[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … of an adjuvant.

Bifidobacterium longum infantis

Glecaprevir

In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [L41080 … The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir

Bordetella pertussis toxoid antigen (formaldehyde inactivated)

Bordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.

Bempedoic acid

[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous

Vernakalant

Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.

Apomorphine

It was first synthesized in 1845 and first used in Parkinson's disease in 1884. … [A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]

Sotalol

Sotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992. … ] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in

Sotrovimab

found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting. … [L41369] Sotrovimab was granted marketing authorization in the European Union in December 2021 under the brand name Xevudy.[L39625,L39620]